Despite expanding treatment options, many patients with chronic spontaneous urticaria (CSU) continue to experience persistent itch and hives that can significantly affect their quality of life. Tune in to hear Ryan Quigley review pooled results from the phase 3 REMIX-1 and REMIX-2 studies, highlighting how remibrutinib delivered rapid symptom relief, sustained disease control through one year, and a favorable long-term safety profile for adults with CSU.
Podden och tillhörande omslagsbild på den här sidan tillhör
ReachMD. Innehållet i podden är skapat av ReachMD och inte av,
eller tillsammans med, Poddtoppen.
